Cargando…

Characterization of V1V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Krachmarov, C, Revesz, K, Prattipati, R, Reichman, C, Lai, Z, Honnen, W, Li, B, Derdeyn, C, Pinter, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441749/ http://dx.doi.org/10.1186/1742-4690-9-S2-O30

Ejemplares similares

Characterization of V1/V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals
por: Krachmarov, C, et al.
Publicado: (2012)

Focusing the immune response on the V3 loop of HIV-1 gp120 induces cross-clade neutralizing
por: Zolla-Pazner, Susan, et al.
Publicado: (2006)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

Computational Prediction of Neutralization Epitopes Targeted by Human Anti-V3 HIV Monoclonal Antibodies
por: Shmelkov, Evgeny, et al.
Publicado: (2014)

Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates
por: Theis, JF, et al.
Publicado: (2012)

Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma
por: Mishra, Nitesh, et al.
Publicado: (2021)

Design clues from functional constraints and broadly neutralizing antibodies
por: Zhou, Tongqing, et al.
Publicado: (2006)

Conformational heterogeneity in V1/V2 domain affects the immunological properties of this region
por: Pinter, A, et al.
Publicado: (2012)

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies
por: Doria-Rose, NA, et al.
Publicado: (2012)

Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology
por: Nemazee, D, et al.
Publicado: (2012)

Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
por: Gorman, Jason, et al.
Publicado: (2015)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

S021-05 OA. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface
por: Song, L, et al.
Publicado: (2009)

Harnessing the protective potential of HIV-1 neutralizing antibodies
por: Smith, S Abigail, et al.
Publicado: (2016)

Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies
por: Bhiman, Jinal N., et al.
Publicado: (2015)

A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch
por: Wang, Zijun, et al.
Publicado: (2020)

S021-06 OA. Potent and broad neutralizing antibodies from HIV-1 non-clade B infected donor reveal a new HIV-1 vaccine target
por: Phogat, SK, et al.
Publicado: (2009)

Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from subtype-C HIV-1 infected north Indians; implications for MPER directed HIV-1 neutralization
por: Andrabi, Raiees, et al.
Publicado: (2012)

Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
por: Vanshylla, Kanika, et al.
Publicado: (2022)

SHIVs, monkeys, and anti-HIV-1 neutralizing antibodies
por: Martin, Malcolm A
Publicado: (2013)

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates
por: Lorenzi, Julio C. C., et al.
Publicado: (2021)

Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject
por: Moody, M, et al.
Publicado: (2012)

Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021)

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals
por: Cheedarla, Narayanaiah, et al.
Publicado: (2017)

Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
por: Bar-On, Yotam, et al.
Publicado: (2018)

In silico prediction of the neutralization range of human anti-HIV monoclonal antibodies
por: Shmelkov, E, et al.
Publicado: (2012)

Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
por: Almond, David, et al.
Publicado: (2012)

Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies
por: Sahoo, Anusmita, et al.
Publicado: (2022)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection
por: Basu, Debby, et al.
Publicado: (2012)

Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
por: Landais, Elise, et al.
Publicado: (2018)

Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies
por: Deshpande, Suprit, et al.
Publicado: (2016)

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
por: Shrestha, Lok Bahadur, et al.
Publicado: (2021)

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
por: Chen, Yanjia, et al.
Publicado: (2022)

Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein
por: Tian, Jianhui, et al.
Publicado: (2016)

A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage
por: Kitchin, D, et al.
Publicado: (2019)

AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
por: van den Berg, Fiona T., et al.
Publicado: (2019)

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
por: Williams, WB, et al.
Publicado: (2012)

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual
por: Guerra, Denise, et al.
Publicado: (2023)

Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes
por: Hioe, Catarina E., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_f8v1irlj9m2p7p3rk8gkkdbatq